Mechanisms and significance of lipoprotein(a) in hepatocellular carcinoma

Hepatobiliary and Pancreatic Diseases International

Volumn 8, Issue 1, 2009, Pages 25-28

  Jiang, Jing Ting ^a   Wu, Chang Ping ^a   Xu, Ning ^b   Zhang, Xue Guang ^a  

^a SOOCHOW UNIVERSITY   (China)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Apolipoprotein(a); Hepatocellular carcinoma; Lipoprotein(a); Metabolism

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A;

CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MARKER; GENE EXPRESSION; GENE LOCATION; GENETIC POLYMORPHISM; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR;

APOPROTEIN(A); CARCINOMA, HEPATOCELLULAR; HUMANS; LIPID METABOLISM; LIPOPROTEIN(A); LIVER; LIVER NEOPLASMS;

EID: 60549094208     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 2006;5:4.
2. Jiang J, Zhang X, Wu C, Qin X, Luo G, et al. Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases. Lipids Health Dis 2008;7:25.
3. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005;9:1221-1232.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
5. Nissen NN, Martin P. Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol 2002;35:S79-85.
6. Zhiqiang G, Zhaohui D, Qinhuan W, Dexian C, Yunyun F, Hongtao L, et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004;38:S175-178.
7. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005;92:607-612.
8. Zhang S, Li L, Lu F. Mortality of primary liver cancer in China from 1990 through 1992. Zhonghua Zhong Liu Za Zhi 1999;21:245-249.
9. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008;7:237-257.
10. Sherlock S. Alcoholic liver disease. Lancet 1995;345:227-229.
11. Jiang JT, Xu N, Zhang XY, Wu CP. Lipids changes in liver cancer. J Zhejiang Univ Sci B 2007;8:398-409.
12. Ooi K, Shiraki K, Sakurai Y, Morishita Y, Nobori T. Clinical significance of abnormal lipoprotein patterns in liver diseases. Int J Mol Med 2005;15:655-660.
13. Motta M, Giugno I, Ruello P, Pistone G, Di Fazio I, Malaguarnera M. Lipoprotein (a) behaviour in patients with hepatocellular carcinoma. Minerva Med 2001;92: 301-305.
14. Cooper ME, Akdeniz A, Hardy KJ. Effects of liver transplantation and resection on lipid parameters: a longitudinal study. Aust N Z J Surg 1996;66:743-746.
15. Byrne CD, Lawn RM. Studies on the structure and function of the apolipoprotein(a) gene. Clin Genet 1994; 46:34-41.
16. Bowden JF, Pritchard PH, Hill JS, Frohlich JJ. Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia. Arterioscler Thromb 1994;14:1561-1568.
17. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun 1993;191:1192-1196.
18. Wade DP, Clarke JG, Lindahl GE, Liu AC, Zysow BR, Meer K, et al. 5′ control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci U S A 1993;90:1369-1373.
19. Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904-910.
20. Hasstedt SJ, Ash KO, Williams RR. A re-examination of major locus hypotheses for high density lipoprotein cholesterol level using 2,170 persons screened in 55 Utah pedigrees. Am J Med Genet 1986;24:57-67.
21. Utermann G, Duba C, Menzel HJ. Genetics of the quantitative Lp(a) lipoprotein trait. II. Inheritance of Lp(a) glycoprotein phenotypes. Hum Genet 1988;78:47-50.
22. Amemiya H, Arinami T, Kikuchi S, Yamakawa-Kobayashi K, Li L, Fujiwara H, et al. Apolipoprotein(a) and pentanucleotide repeat polymorphisms are associated with the degree of atherosclerosis in coronary heart disease. Atherosclerosis 1996;123:181-191.
23. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132-137.
24. Romics L, Nemesánszky E, Szalay F, Császár A, Tresch J, Karádi I. Lipoprotein(a) concentration and phenotypes in primary biliary cirrhosis. Clin Chim Acta 1996;255:165-171.
25. Gaubatz JW, Ghanem KI, Guevara J Jr, Nava ML, Patsch W, Morrisett JD. Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a]. J Lipid Res 1990;31:603-613.
26. Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Abe A, et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996;16:713-719.
27. Berg K. A New Serum Type System in Man - the Lp System. Acta Pathol Microbiol Scand 1963;59:369-382.
28. Dahlén GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994;108:111-126.
29. Tietge UJ, Boker KH, Bahr MJ, Weinberg S, Pichlmayr R, Schmidt HH, et al. Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. Hepatogastroenterology 1998;45:2255-2560.
30. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989;78:145-150.
31. Malaguarnera M, Giugno I, Trovato BA, Panebianco MP. Restuccia N, Ruello P. Lipoprotein(a) in cirrhosis. A new index of liver functions? Curr Med Res Opin 1996;13:479-485.
32. Krempler F, Kostner GM, Roscher A, Haslauer F, Bolzano K, Sandhofer F. Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. J Clin Invest 1983;71:1431-1441.
33. Geiss HC, Ritter MM, Richter WO, Schwandt P, Zachoval R. Low lipoprotein (a) levels during acute viral hepatitis. Hepatology 1996;24:1334-1337.
34. Scanu AM. Structural basis for the presumptive atherothrombogenic action of lipoprotein(a). Facts and speculations. Biochem Pharmacol 1993;46:1675-1680.
35. Klausen IC, Beisiegel U, Menzel HJ, Rosseneu M, Nicaud V, Faergeman O. Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction. The EARS Study. European Atherosclerosis Research Study. Arterioscler Thromb Vasc Biol 1995;15:1001-1008.
36. Ferraro M, Spagnuolo V, Sprovieri M, Mauro GF. Lipoprotein (a) and stroke. Minerva Med 2008;99:399-409.
37. Spinler SA, Cziraky MJ. Lipoprotein(A): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy. Ann Pharmacother 1994;28: 343-351.
38. Malaguarnera M, Trovato G, Restuccia S, Giugno I, Franzé CM, Receputo G, et al. Treatment of nonresectable hepatocellular carcinoma: review of the literature and meta-analysis. Adv Ther 1994; 11;303-319.
39. Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989;83:137-142.
40. Samonakis DN, Koutroubakis IE, Sfiridaki A, Malliaraki N, Antoniou P, Romanos J, et al. Hypercoagulable states in patients with hepatocellular carcinoma. Dig Dis Sci 2004; 49:854-858.
41. Phillips GB. The lipid composition of serum in patients with liver disease. J Clin Invest 1960;39:1639-1650.
42. Higuchi K, Hospattankar AV, Law SW, Meglin N, Cortright J, Brewer HB Jr. Human apolipoprotein B (apoB) mRNA: identification of two distinct apoB mRNAs, an mRNA with the apoB-100 sequence and an apoB mRNA containing a premature in-frame translational stop codon, in both liver and intestine. Proc Natl Acad Sci U S A 1988; 85:1772-1776.
43. Langstein HN, Norton JA. Mechanisms of cancer cachexia. Hematol Oncol Clin North Am 1991;5:103-123.
44. Scanu AM, Bamba R. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. Am J Cardiol 2008;10:44B-47B.
45. Albers JJ, Adolphson JL, Hazzard WR. Radioimmunoassay of human plasma Lp(a) lipoprotein. J Lipid Res 1977;18: 331-338.
46. Motta M, Pistone G, Franzone AM, Romeo MA, Di Mauro S, Giugno I, et al. Antibodies against ox-LDL serum levels in patients with hepatocellular carcinoma. Panminerva Med 2003;45:69-73.